#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)



# option care health<sup>®</sup>

# **OPTION CARE HEALTH, INC.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

<u>001-11993</u> (Commission File Number) <u>05-0489664</u> (IRS Employer Identification Number)

<u>3000 Lakeside Dr. Suite 300N, Bannockburn, IL 60015</u> (Address of principal executive offices)

(312) 940-2443

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- □ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- □ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- □ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  $\Box$ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol(s)	Name of each exchange on which registered					
Common Stock, \$0.0001 par value per share	OPCH	Nasdaq Global Select Market					

#### Item 2.02. Results of Operations and Financial Condition.

On February 22, 2024, Option Care Health, Inc. (the "Company") issued a press release reporting its fourth quarter and full-year 2023 financial results. A copy of the press release is furnished with this Form 8-K and attached hereto as Exhibit 99.1.

The press release includes certain non-GAAP financial measures described therein. Reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.

The information in this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

#### Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
<u>99.1</u>	Press release dated February 22, 2024

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **Option Care Health, Inc.**

Date: February 22, 2024

By: /s/ Michael Shapiro

Michael Shapiro Chief Financial Officer



### **OPTION CARE HEALTH REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2023**

**BANNOCKBURN, IL., February 22, 2024** - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2023.

### Fourth Quarter 2023 Financial Highlights

- Net revenue of \$1,124.4 million, up 9.5% compared to \$1,027.2 million in the fourth quarter of 2022
- Gross profit of \$247.1 million, or 22.0% of revenue, up 6.9% compared to \$231.1 million, or 22.5% of revenue, in the fourth quarter of 2022
- Net income of \$57.2 million, or \$0.32 earnings per share, inclusive of the impact from non-operating income, compared to net income of \$47.5 million, or \$0.26 earnings per share in the fourth quarter of 2022
- Adjusted EBITDA of \$111.6 million, up 18.4% compared to \$94.3 million in the fourth quarter of 2022
- Cash flow from operations of \$51.0 million, and cash balances of \$343.8 million at the end of the fourth quarter
- The Company announced that it fulfilled \$250 million in share repurchases and the Board of Directors authorized an additional \$250 million share repurchase authorization

### **Full Year 2023 Financial Highlights**

- Net revenue of \$4,302.3 million, up 9.1% compared to \$3,944.7 million in full year 2022
- Gross profit of \$981.2 million, or 22.8% of revenue, up 13.2% compared to \$866.9 million, or 22.0% of revenue, in full year 2022
- Net income of \$267.1 million, or \$1.48 diluted earnings per share, compared to net income of \$150.6 million, or \$0.83 earnings per share, in full year 2022
- Adjusted EBITDA of \$425.2 million, up 24.0% compared to \$342.9 million in full year 2022
- Cash flow from operations of \$371.3 million, up 38.8% compared to \$267.5 million in full year 2022

John C. Rademacher, Chief Executive Officer, commented, "The Option Care Health team delivered strong financial results in the fourth quarter and full year of 2023 and continued to execute on our commitment to clinical excellence by providing extraordinary patient care through our resilient national platform. The patient is at the center of everything we do, and I am excited to build on this momentum in 2024 to further our mission to provide innovative services that improve outcomes, reduce costs, and deliver hope for patients and families."

# Full Year 2024 Financial Guidance

For the full year 2024, Option Care Health expects to deliver the following financial results:

- Net revenue of \$4.6 billion to \$4.8 billion
- Adjusted EBITDA of \$425 million to \$450 million
- Cash flow from operations of at least \$300 million

Additionally, the Company anticipates an effective tax rate of 26% - 28% and net interest expense of approximately \$55 million to \$60 million.

## **Conference Call**

Option Care Health will host a conference call to discuss its financial results later today at 8:30 a.m. EST. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

# About Option Care Health

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,500 team members, including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at <u>OptionCareHealth.com</u>.

## **Investor Contacts**

Mike Shapiro Chief Financial Officer T: (312) 940-2538 <u>mike.shapiro@optioncare.com</u>

Bob East, Asher Dewhurst, Jordan Kohnstam Westwicke T: (413) 213-0500 <u>optioncarehealth@westwicke.com</u>

# Forward-Looking Statements - Safe Harbor

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

## Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or

a measure of the Company's liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long-lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health's business operations and facilitates comparisons to the Company's historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.

#### OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS)(UNAUDITED)

	December 31, 2023 2022				
	 2023				
ASSETS					
CURRENT ASSETS:					
Cash and cash equivalents	\$ 343,849	\$	294,186		
Accounts receivable, net	377,658		377,542		
Inventories	274,004		224,281		
Prepaid expenses and other current assets	98,744		98,330		
Total current assets	1,094,255		994,339		
NONCURRENT ASSETS:					
Property and equipment, net	120,630		108,321		
Intangible assets, net	20,092		22,371		
Referral sources, net	315,304		341,744		
Goodwill	1,540,246		1,533,424		
Other noncurrent assets	126,508		112,737		
Total noncurrent assets	2,122,780		2,118,597		
TOTAL ASSETS	\$ 3,217,035	\$	3,112,936		
LIABILITIES AND STOCKHOLDERS' EQUITY					
CURRENT LIABILITIES:					
Accounts payable	\$ 426,513	\$	378,763		
Other current liabilities	191,796		186,588		
Total current liabilities	 618,309		565,351		
NONCURRENT LIABILITIES:					
Long-term debt, net of discount, deferred financing costs and current portion	1,056,650		1,058,204		
Other noncurrent liabilities	120,404		103,278		
Total noncurrent liabilities	 1,177,054		1,161,482		
Total liabilities	 1,795,363		1,726,833		
STOCKHOLDERS' EQUITY	1,421,672		1,386,103		
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 3,217,035	\$	3,112,936		

### OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

	Three Months Ended December 31,			Year Ended December 31,			
	2023		2022		2023		2022
NET REVENUE	\$ 1,124,390	\$	1,027,213	\$	4,302,324	\$	3,944,735
COST OF REVENUE	877,267		796,132		3,321,101		3,077,817
GROSS PROFIT	247,123		231,081		981,223		866,918
OPERATING COSTS AND EXPENSES:							
Selling, general and administrative expenses	147,783		148,351		607,427		566,122
Depreciation and amortization expense	14,784		14,538		59,201		60,565
Total operating expenses	 162,567		162,889		666,628	-	626,687
OPERATING INCOME	 84,556		68,192		314,595		240,231
OTHER INCOME (EXPENSE):							
Interest expense, net	(12,432)		(14,798)		(51,248)		(53,806)
Other, net	6,801		11,387		95,395		19,343
Total other (expense) income	 (5,631)		(3,411)		44,147		(34,463)
INCOME BEFORE INCOME TAXES	78,925		64,781		358,742		205,768
INCOME TAX EXPENSE	21,748		17,252		91,652		55,212
NET INCOME	\$ 57,177	\$	47,529	\$	267,090	\$	150,556
Earnings per share, basic	\$ 0.32	\$	0.26	\$	1.49	\$	0.83
Earnings per share, diluted	\$ 0.32	\$	0.26	\$	1.48	\$	0.83
Weighted average common shares outstanding, basic	176,055		181,925		178,973		181,105
Weighted average common shares outstanding, diluted	 177,743		183,086	_	180,375		182,075

### OPTION CARE HEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS)(UNAUDITED)

	Year Ended December 31,				
	 2023	202	2		
CASH FLOWS FROM OPERATING ACTIVITIES:					
Net income	\$ 267,090	\$	150,556		
Adjustments to reconcile net income to net cash provided by operations:					
Depreciation and amortization expense	62,200		65,434		
Deferred income taxes - net	12,766		49,187		
Other non-cash adjustments	50,684		32,147		
Changes in operating assets and liabilities:					
Accounts receivable, net	224		(36,889)		
Inventories	(51,000)		(41,010)		
Accounts payable	47,703		98,885		
Other	(18,372)		(50,763)		
Net cash provided by operating activities	 371,295		267,547		
CASH FLOWS FROM INVESTING ACTIVITIES:					
Acquisition of property and equipment	(41,866)		(35,358)		
Proceeds from sale of assets	3,743		14,670		
Business acquisitions, net of cash acquired	(12,494)		(87,364)		
Other investing activities	(5,889)		(07,504)		
Net cash used in investing activities	 (56,506)		(108,052)		
CASH FLOWS FROM FINANCING ACTIVITIES:			20.01.6		
Proceeds from warrant exercises			20,916		
Purchase of company stock	(250,261)				
Other financing activities	 (14,865)		(5,648)		
Net cash (used in) provided by financing activities	 (265,126)		15,268		
NET INCREASE IN CASH AND CASH EQUIVALENTS	49,663		174,763		
Cash and cash equivalents - beginning of the period	294,186		119,423		
CASH AND CASH EQUIVALENTS - END OF PERIOD	\$ 343,849	\$	294,186		

#### OPTION CARE HEALTH, INC. RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES (IN THOUSANDS)(UNAUDITED)

	Three Months Ended December 31,			Year Ended December 31,			
	2023		2022		2023		2022
Net income	\$ 57,177	\$	47,529	\$	267,090	\$	150,556
Interest expense, net	12,432		14,798		51,248		53,806
Income tax expense	21,748		17,252		91,652		55,212
Depreciation and amortization expense	15,777		15,711		62,200		65,434
EBITDA	107,134		95,290		472,190		325,008
EBITDA adjustments							
Stock-based incentive compensation expense	7,571		4,202		30,479		16,783
Gain on sale of assets	_		(10,325)		—		(10,325)
Restructuring, acquisition, integration and other (1)	(3,103)		5,105		(77,486)		11,387
Adjusted EBITDA	\$ 111,602	\$	94,272	\$	425,183	\$	342,853

(1) Restructuring, acquisition, integration and other for the year ended December 31, 2023 includes the Amedisys merger termination fee, net of mergerrelated expenses